A key gene modulating oxytocin efficacy in autism: genome-wide discovery and verification in randomized controlled trials datasets.

This was a randomised controlled trial — people were assigned to treatments by chance, which is the most reliable way to tell whether a treatment itself caused a change.

The number of people who took part is not stated in this record, so the result cannot be judged on size.

The abstract does not include a conclusions section, so this page does not state what the researchers concluded.

This record does not state:

• the ages of the people who took part
• how long the study ran

This is a plain-language summary of one paper's abstract, not medical advice. Talk to your child's clinician before changing anything.

Journal: Molecular psychiatry

Year: 2026

Design: Randomized Controlled Trial

Intervention: oxytocin

Authors: Hitoshi Kuwabara, Masaki Kojima, Seico Benner, Takeshi Otowa, Takamitsu Watanabe, Miho Kuroda, Keiho Owada, Walid Yassin, Junko Hamada, Yukiko Kano, Yota Uno, Itaru Kushima, Daisuke Mori, Yuko Arioka, Toshio Munesue, Kiyoto Kasai, Haruhiro Higashida, Osamu Abe, Hidemasa Takao, Tomoyasu Wakuda, Yosuke Kameno, Jun Inoue, Taeko Harada, Aya Yamauchi, Nanayo Ogawa, Nami Honda, Saya Kikuchi, Moe Seto, Hiroaki Tomita, Noriko Miyoshi, Megumi Matsumoto, Yuko Kawaguchi, Koji Kanai, Manabu Ikeda, Itta Nakamura, Shuichi Isomura, Yoji Hirano, Toshiaki Onitsuka, Nagahide Takahashi, Mitsuko Nakashima, Hirotomo Saitsu, Kenji Kondo, Masashi Ikeda, Nakao Iwata, Mihoko Shimada, Tsukasa Sasaki, Nori Takei, Norio Ozaki, Hirotaka Kosaka, Takashi Okada, Hidenori Yamasue

Previous studies suggest that oxytocin has therapeutic potential for modulating core symptoms of autism spectrum disorder (ASD), although findings have been inconsistent. The unknown mechanisms underlying oxytocin's effects and the substantial individual variability in treatment response impede the development of effective oxytocin-based therapies. In this study, we conducted a genome-wide association study (GWAS) using data from a randomized controlled trial (RCT) that examined the effects of a single dose oxytocin on behavioral and neural correlates of ASD. We further tested the association between the SNP identified in the GWAS and clinical efficacy in an independent, larger dataset comprising participants from three additional RCTs. In these trials, males with high-functioning ASD received repeated doses of oxytocin, and treatment response was assessed using the social reciprocity domain of the Autism Diagnostic Observation Schedule (ADOS), the common primary outcome across all three studies. The GWAS identified a significant association between oxytocin-induced improvements in medial prefrontal cortex activity during a social judgment task and the single nucleotide polymorphism (SNP) rs1871303 in the ryanodine receptor 2 (RYR2) gene (β = 2.37, t = 7.82, df = 72, P = 3.47 × 10⁻⁹). The validation analysis supported the association between this RYR2 SNP and individual variability in ADOS reciprocity improvement (β = 0.194, t = 2.30, df = 135, P = 0.023), with no significant association observed for placebo response (P > 0.1). To our knowledge, this is the first GWAS to investigate the pharmacogenomics of oxytocin efficacy in ASD. These findings highlight RYR2 as a key gene influencing oxytocin response, possibly through its role in calcium channel signaling and regulation of endogenous oxytocin release.

Molecular psychiatry, 2026

PMID 41904269

DOI 10.1038/s41380-026-03562-y

This record was extracted from the paper's PubMed abstract and metadata. Full-text methods and risk-of-bias details were not reviewed.